BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
Retrieved on:
Friday, February 23, 2024
Incidence, AAAAI, Pharmacy, Attack, Expert network, Tranexamic acid, Prior, Effectiveness, Pharmacist, Washington Convention Center, University, Conditional sentence, Day, Lanadelumab, Safety, Androgen, HAE, History, Hereditary angioedema, Tolerability, Monitoring, Internal medicine, Walter, BioCryst Pharmaceuticals, Medicine, Disease, Ageing, Observational study, Poster, American Academy, Pharmaceutical industry
“These additional analyses of real-world use of ORLADEYO show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with ORLADEYO.
Key Points:
- “These additional analyses of real-world use of ORLADEYO show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with ORLADEYO.
- These analyses present the overall attack rate progression and attack rate progression stratified by severity (i.e., number of attacks at baseline), prior prophylaxis and C1-INH level and function.
- These findings further demonstrate that ORLADEYO can help maintain disease control in patients with lower baseline attack rates and further reduce attack rates in patients with more active disease.
- Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes; Poster #012; Friday, February 23, 3:15-4:15 p.m.